BI 770371 + pembrolizumab

**BI 770371 + pembrolizumab** is an experimental combination therapy being investigated primarily in advanced or metastatic cancers, notably head and neck squamous cell carcinoma. **BI 770371** is a next-generation monoclonal antibody (IgG1) that antagonizes both V1 and V2 variants of SIRPα (signal regulatory protein alpha), disrupting the CD47/SIRPα "don't eat me" signal that allows tumor cells to evade the innate immune system. **Pembrolizumab** is a well-established anti-PD-1 monoclonal antibody checkpoint inhibitor that blocks PD-1 on immune cells, enabling the immune system to better recognize and destroy cancer cells. This combination is being tested for potential synergy, enhancing antitumor immune responses beyond those seen with either drug alone.